Skip to main content
SpringerLink
Log in

Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors

  • Esophagus (E Dellon, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Proton pump inhibitors (PPI) are among the safest class of drugs used by all care providers, including gastroenterologists. They are the mainstay in treatment of acid-related disease, in particular, gastroesophageal reflux disease. Without them, many patients would experience a major decrement in their quality of life. However, no drug is without side effects or adverse events. In the past decade, numerous reports, principally case control studies and meta-analyses, have raised questions about important adverse events related to the use of PPIs. This has affected not only physicians’ prescribing habits but patients’ concerns about using these medications, particularly long term. Several FDA warnings are listed including those related to long bone fractures, interaction with clopidogrel, enteric infections, and hypomagnesaemia. More recently, concerns regarding PPIs and cardiovascular events have resurfaced as have issues related to kidney disease and dementia. The methodology of these studies allows us to find an association with these events but does not provide us with sufficient evidence to determine causality. In general, the findings of the available studies do not fit with our clinical experience nor is the magnitude of the association sufficient to result in a major change in our practice. Nevertheless, the recent literature has resulted in our careful reevaluation of PPI use across both FDA indications and in general. This article will critically review the literature regarding potential PPI adverse events and attempt to place them in perspective for the practicing physician.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Katz P, Kahrilas P, Johnson D, et al. Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors. Therap Adv Gastroenterol. 2015;8(6):322–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wilder-Smith C, Backlund A, Eckerwall G, Lind T, Fjellman M, Rohss K. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig. 2008;28(6):333–43.

    Article  CAS  PubMed  Google Scholar 

  3. Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther. 1998;12(12):1241–7.

    Article  CAS  PubMed  Google Scholar 

  4. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63.

    Article  CAS  PubMed  Google Scholar 

  5. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006;55(9):1217–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–7.

    Article  CAS  PubMed  Google Scholar 

  7. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–7.

    Article  CAS  PubMed  Google Scholar 

  8. Frelinger III AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–11.

    Article  CAS  PubMed  Google Scholar 

  9. •• Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248. An excellent meta-analysis outlning association of multiple cardiac issues and PPI use. Offers clarity among numerous studies.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.

    Article  CAS  PubMed  Google Scholar 

  11. Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140(3):791–8.

    Article  CAS  PubMed  Google Scholar 

  12. Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.

    Article  CAS  PubMed  Google Scholar 

  13. • Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653. A pharmacovigilance, data mining study widely publicized by the lay press with complex methodology. Very difficult to completely accept methodology.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ghebremariam YT, Cooke JP, Khan F, et al. Proton pump inhibitors and vascular function: a prospective cross-over pilot study. Vasc Med. 2010;20(4):309–16.

    Article  Google Scholar 

  15. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86.

    Article  PubMed  Google Scholar 

  16. Turkiewicz A, Vicente RP, Ohlsson H, Tyden P, Merlo J. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction—a case-crossover analysis. Eur J Clin Pharmacol. 2015;71(1):125–9.

    Article  CAS  PubMed  Google Scholar 

  17. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292–7.

    Article  PubMed  Google Scholar 

  18. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419–28.

    Article  PubMed  Google Scholar 

  19. •• Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–4. Large database study from Germany offering an association between PPI use and dementia. Sample size is quite large understanding how dementia was coded not easy to do.

    Article  PubMed  Google Scholar 

  20. • Larazus B, Chen Y, Wilson F, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46. A case control study of two large databases. Shows consistent association of development of chronic kidney disease with PPIs. Size and consistency to results are strengths. Plausible etiology for CKD not clear from the study.

    Article  Google Scholar 

  21. Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 27: 2016.

  22. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104(5):422–30.

    Article  CAS  PubMed  Google Scholar 

  23. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.

    Article  PubMed  Google Scholar 

  24. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.

    Article  CAS  PubMed  Google Scholar 

  25. Koulouridis I, Alfayez M, Tighiouart H, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis. 2013;62(4):730–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. • Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74. A randomized prospective trial examing multiple outcomes. This study looked in part at laboratory data (magnesium, calcium, iron) showing no difference in medcial and surgical groups.

    Article  CAS  PubMed  Google Scholar 

  27. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896–903.

    Article  CAS  PubMed  Google Scholar 

  28. den Elzen WP, Groeneveld Y, De RW, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008;27(6):491–7.

    Article  Google Scholar 

  29. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27(11):1110–21.

    Article  CAS  PubMed  Google Scholar 

  30. Kopic S, Geibel JP. Gastric acid, calcium absorption, and their impact on bone health. Physiol Rev. 2013;93(1):189–268.

    Article  CAS  PubMed  Google Scholar 

  31. Mattsson JP, Vaananen K, Wallmark B, et al. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1991;1065(2):261–8.

    Article  CAS  PubMed  Google Scholar 

  32. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.

    Article  CAS  PubMed  Google Scholar 

  34. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.

    Article  CAS  PubMed  Google Scholar 

  37. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786–95.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18. quiz 1219

    Article  CAS  PubMed  Google Scholar 

  39. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56.

    Article  PubMed  Google Scholar 

  40. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, et al. Risk factors for Salmonella enteritidis and typhimurium (DT104 and non-DT104) infections in the Netherlands: predominant roles for raw eggs in enteritidis and sandboxes in typhimurium infections. Epidemiol Infect. 2006;134(3):617–26.

    Article  CAS  PubMed  Google Scholar 

  41. Freeman R, Dabrera G, Lane C, et al. Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella mikawasima in the UK. Epidemiol Infect. 2013;2015:1–8.

    Google Scholar 

  42. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, et al. Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in the Netherlands: a case-control study. Epidemiol Infect. 2010;138(10):1391–404.

    Article  CAS  PubMed  Google Scholar 

  43. DuPont HL, Formal SB, Hornick RB, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med. 1971;285(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  44. Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11–12):1269–81.

    Article  CAS  PubMed  Google Scholar 

  45. Diemert DJ. Prevention and self-treatment of traveler’s diarrhea. Clin Microbiol Rev. 2006;19(3):583–94.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Juckett G. Prevention and treatment of traveler’s diarrhea. Am Fam Physician. 1999;60(1):119–24.

    CAS  PubMed  Google Scholar 

  47. Schwille-Kiuntke J, Mazurak N, Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers’ diarrhoea. Aliment Pharmacol Ther. 2015;41(11):1029–37.

    Article  CAS  PubMed  Google Scholar 

  48. Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther. 2009;29(6):626–34.

    Article  CAS  PubMed  Google Scholar 

  49. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.

    Article  CAS  PubMed  Google Scholar 

  50. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(3):381–90.

    Article  PubMed  Google Scholar 

  51. FDA drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Food and Drug Administration.

Further reading

  1. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8):2883–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jay Monahan Center for Gastrointestinal Health, Department of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA

    Felice Schnoll-Sussman MD

  2. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

    Philip O. Katz MD

  3. Division of Gastroenterology, Einstein Medical Center, Philadelphia, PA, USA

    Philip O. Katz MD

Authors
  1. Felice Schnoll-Sussman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip O. Katz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip O. Katz MD.

Ethics declarations

Conflict of Interest

Felice Schnoll-Sussman declares no potential conflicts of interest. Philip O. Katz is a consultant for Pfizer Consumer Health and Torax and a speaker for Medtronic.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Esophagus

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schnoll-Sussman, F., Katz, P.O. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Curr Treat Options Gastro 15, 1–9 (2017). https://doi.org/10.1007/s11938-017-0115-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-017-0115-5

Keywords

Search

Navigation